The Department of Public Health at Weill Cornell Medical College and NewYork-Presbyterian Hospital/Weill Cornell Medical Center has created a new Division of Biostatistics and Epidemiology, appointing Dr. Madhu Mazumdar, a biostatistician at Memorial-Sloan Kettering Cancer Center, as chief. Dr. Mazumdar has also been named associate professor of public health at Weill Cornell Medical College and associate attending physician at NewYork-Presbyterian/Weill Cornell.
"Biostatistics and epidemiology â€“ the study of the
patterns and causes of health and disease â€“ play an important role in
public-health research, from planning and evaluating the design of
research studies to developing new analytical methods and drawing valid
conclusions from statistical results," said Dr. Alvin Mushlin, chairman
of the Department of Public Health at Weill Cornell Medical College and
public health physician-in-chief at NewYork Presbyterian/Weill Cornell.
"Dr. Madhu Mazumdar is uniquely qualified to lead this important new
The new Division will support and encourage clinical
and laboratory research, population-based health behavior research, and
research in the field of computational biomedicine. Statisticians in
the division, which includes the Biostatistics and Research Methodology
CORE, will assist with design and analysis of research studies, and
develop and participate in introductory and advanced quantitative
methodology courses. Additionally, faculty will carry out
methodological research on statistical and epidemiological methods.
"The Division will be a resource for the entire
scientific community at Weill Cornell and beyond. Working closely with
researchers in other disciplines, we will help formulate innovative
research hypotheses, provide proper study design, and analyze research
with cutting-edge data analysis methods," said Dr. Mazumdar. "I seek to
create a model of quantitative collaboration where the
statistician/epidemiologist works closely with clinical researchers as
part of a research team thereby benefiting the clinical project as well
as improving the quantitative methodology."
Dr. Mazumdar's current research interests are in the
areas of optimization of therapeutic response evaluation criteria,
development of group sequential design (GSD) for comparative diagnostic
accuracy studies, assessment of quality of life and economic
consequences of cancer treatment for long-term survivors, and
approaches to design and analysis of matched data in the censored
At Memorial Sloan-Kettering, Dr. Mazumdar performed
research on methods of finding optimal "cutpoints" to answer clinical
questions of identification of high-risk testicular cancer patients who
need additional surgery for resecting a residual mass. She developed a
standardization method for adjusting the effect of patient selection in
phase II clinical trials for bladder cancer, to interpret the value of
a phase II study in the context of historical controls, to rank
outcomes of various phase II studies, and to aid in the decision-making
process of whether to progress to a randomized phase III trial.
Photo by Weill Cornell Art & Photo.
|Dr. Madhu Mazumdar|